Consequences of mitotic slippage for antimicrotubule drug therapy
- 1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
- 2School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
- 3A*STAR Institute of Molecular and Cell Biology, Singapore, Singapore
- 4Department of Medicine, Imperial College London, London, UK
- Correspondence should be addressed to K Crasta; Email: kccrasta{at}ntu.edu.sg
-
Figure 1
Different cell fates following antimicrotubule drug treatment. Cancer cells treated with antimicrotubule drugs go through a prolonged mitotic arrest that can culminate in mitotic cell death. Mitotically arrested cells can also take an alternative route known as mitotic slippage and escape mitotic cell death. Here, cells exit mitosis prematurely, without proper chromosome segregation and cytokinesis, and enter the next interphase as multinucleated tetraploid cells. The main post-slippage cell fates are shown: cells either undergo a G1 arrest, often leading to senescence or post-slippage cell death.
-
Figure 2
Different cell fates following antimicrotubule drug treatment. Cells can undergo mitotic slippage-induced senescence after antimicrotubule drug treatment. These cells are capable of eliciting the senescence-associated secretory phenotype (SASP) that confer paracrine pro-tumourigenic effects such as cell proliferation, migration, invasion and angiogenesis. This can potentially contribute to the emergence of acquired chemoresistance.
- © 2017 Society for Endocrinology
